Who was studied?
One patient with driver-negative NSCLC, brain metastases and leptomeningeal metastases.
What does the publication report?
The abstract reports resolution of lesions and PFS of 69 months at follow-up.
Safety findings
A detailed graded safety account is not provided in the abstract.
How should we interpret it?
A single patient cannot establish efficacy or predict an individual outcome. Prior and concurrent treatments limit attribution.
Read the original source
This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.
Long-term survival in a patient with leptomeningeal metastases from non-small cell lung cancer treated with stereotactic radiotherapy (SRT), programmed cell death protein 1 (PD-1) inhibitor, and granulocyte-macrophage colony-stimulating factor (GM-CSF): a case report · DOI: 10.21037/tcr-2025-1088 · PMID: 41378009
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.